Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data …

Pivotal Trial of Cynapsus’ Under-the-Tongue Apomorphine Formulation Will IncludeTechnology-Enabled Sub-Study to Gather and Analyze Objective Patient Data on Disease Progression and Medication EffectEffort Builds on Ongoing Data Science Collaboration BetweenMichael J. Fox Foundation and Intel CorporationTORONTO and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) and The Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) today announced that they are working together to incorporate wearable device technology and “big data” approaches into Cynapsus’ pivotal Phase 3 clinical study of APL-130277, a sublingual (under-the-tongue) formulation of apomorphine to treat (“OFF”) episodes in Parkinson’s disease (“PD”) patients.This is a pilot effort to understand how clinical studies can harness data science approaches to objectively measure disease progression with the goal of speeding progress toward breakthroughs in drug development.…


Link to Full Article: Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data …